FibroBiologics, Inc. announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model. The organoid, composed of fibroblasts and thymus derived cells, is capable of generating mature and diverse T cells, including CD4, CD8, and regulatory T cells, in vitro and in vivo. FibroBiologics intends to develop this technology as a subcutaneous injection of an allogeneic fibroblast-based organoid to restore thymus function lost due to age-related natural thymus involution, and for a rapid restoration of the immune system in patients who have gone through chemotherapy.